Akebia to Host Conference Call on March 6th to Discuss Full-Year 2016 Financial Results and Corporate Highlights

CAMBRIDGE, Mass.--()--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company will host a conference call on Monday, March 6, 2017 at 4:30 PM ET to discuss the financial results for the year ended December 31, 2016, and recent corporate highlights.

Conference Call and Webcast

   
Date: March 6, 2017
 
Time 4:30 PM ET
 

Telephone Access:

Domestic Callers: dial (877) 458-0977

International Callers: dial (484) 653-6724

Please reference the Akebia conference call

Passcode: 77605143

 

Online Access:

Go to the Investor Relations section of the Akebia website and follow instructions for accessing the live webcast. Please connect to the website at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. An archived presentation will be available for 90 days.

 

Telephone Replay:

A telephone replay will be available for 5 days following the call.

Replay for domestic Callers: dial (855) 859-2056

Replay for international Callers: dial (404) 537-3406

Passcode: 77605143

 

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia's lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at www.akebia.com.

Contacts

Akebia Therapeutics, Inc.
Theresa McNeely, 617-844-6113
SVP, Corporate Communications and Investor Relations
Tmcneely@akebia.com

Recent Stories

RSS feed for Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.